Amir Abolfathi, CEO

Amir has over 26 years of operating experience in the healthcare industry focused on developing and commercializing cardiovascular devices, dental products, hearing prosthetics, and genomic diagnostics & analytics. Amir was the inventor and founder of Sonitus Medical in 2006, a novel non-surgical hearing prosthetic designed for treatment of unilateral deafness, and Sonitus Technologies in 2010.  Prior to Sonitus, Amir held a variety of executive positions at Align Technology, Embolic Protection, and EndoTex as well as engineering roles at Pfizer, Guidant, and Baxter-Edwards.  Amir holds over 100 issued patents.

Amir received an MS in Engineering Management from the University of Southern California and a BS in Biomedical Engineering from the University of California, San Diego.

Eric Goldfarb, VP R&D/Operations

Eric is a seasoned research and development leader, most recently as VP of R&D at Nuelle.  Prior to Nuelle, Eric was Director of R&D for Acclarent, focusing on development of the rhinology platform.  Before joining Acclarent, Eric was Director of R&D for Evalve, an early innovator in the rapidly-growing heart valve repair market.  Eric holds over 50 issued patents.  

Eric holds a BA in Biology from Dartmouth College and an MSE in Mechanical Engineering from Stanford University.


Laura England, VP Clinical

Laura has broad experience in research and development, encompassing a wide variety of scientific areas.  Most recently, Laura was Director of Clinical Research for Acclarent, responsible for the development and execution of clinical programs for novel Ear, Nose, and Throat Devices.  Prior to Acclarent, Laura held various senior management and scientific roles within the medical device and pharmaceutical companies Solta Medical and Fibrogen.

Laura has a BS in Genetics & Cell Biology from the University of Minnesota and a PhD in Biochemistry & Molecular Biology from the University of California, Berkeley. 

Dan Harfe, VP Regulatory/Quality/Strategy

Dan has operational expertise in a broad array of medical device functions, most recently as Sr. Director of Clinical and Regulatory for Acclarent, a developer of innovative Ear, Nose, and Throat technology.  Previously, Dan held management positions in marketing and business development at Guidant, and as an engineering manager at Lockheed Martin Space Operations.  

Dan received a BSE in Biomedical Engineering from Duke University, an MSE in Biomedical Engineering from Tulane University, and an MBA from Stanford University.

Mitchell Sugarman, Head of Health Economics, Policy and Payment

Mitchell Sugarman.png

Mitchell Sugarman brings a wealth of diverse Health Economic and Technology Assessment expertise to Tusker Medical.  Mitch was most recently the Vice President of Global Health Economics, Policy and Payment for Medtronic’s CardioVascular Division, responsible for ensuring that reimbursement was a consideration in every functional area from product conception through launch. Mitch’s primary objective was to ensure that providers and payers had the right information in order to make appropriate coding, coverage and payment decisions. 

Prior to joining Medtronic, Mitch worked at Kaiser Permanente for 19 years initially as the Director of the Clinical Genetics Department, and later as the Director of Medical Technology Assessment.  Having worked on both the payer/provider side of health care at Kaiser Permanente, and the industry side at Medtronic, Inc., Mitch has a unique perspective on health technology assessment and the need to use this discipline in a practical and effective manner.